Advertisement
Advertisement
EVGN
EVOGENE LTD.
0.85
USDSponsored
-0.05
-5.24%
Mar 25, 15:59 UTC -4
Closed
Pre-Market
0.83
-0.02
-1.98%
EVGN Earnings Reports
Positive Surprise Ratio
EVGN beat 15 of 30 last estimates.
50%
Next Report
Date of Next Report
May 19, 2026
Estimate for Q1 26 (Revenue/ EPS)
$357.00K
/-$0.27
Implied change from Q4 25 (Revenue/ EPS)
+13.69%
/-55.74%
Implied change from Q1 25 (Revenue/ EPS)
-85.39%
/-28.95%
EVOGENE LTD. earnings per share and revenue
On Mar 05, 2026, EVGN reported earnings of -0.61 USD per share (EPS) for Q4 25, missing the estimate of -0.26 USD, resulting in a -130.02% surprise. Revenue reached 314.00 thousand, compared to an expected 280.50 thousand, with a 11.94% difference. The market reacted with a -6.16% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 3 analysts forecast an EPS of -0.27 USD, with revenue projected to reach 357.00 thousand USD, implying an decrease of -55.74% EPS, and increase of 13.69% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
BioCardia, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.17
Actual
-$0.06
Surprise
+65.40%
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
FAQ
What were EVOGENE LTD.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, EVOGENE LTD. reported EPS of -$0.61, missing estimates by -130.02%, and revenue of $314.00K, 11.94% above expectations.
How did the market react to EVOGENE LTD.'s Q4 2025 earnings?
The stock price moved down -6.16%, changed from $0.84 before the earnings release to $0.79 the day after.
When is EVOGENE LTD. expected to report next?
The next earning report is scheduled for May 19, 2026.
What are the forecasts for EVOGENE LTD.'s next earnings report?
Based on 3
analysts, EVOGENE LTD. is expected to report EPS of -$0.27 and revenue of $357.00K for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement